# Reducing Proviral HIV DNA With Interferon-a

> **NCT02227277** · PHASE2 · UNKNOWN · sponsor: **The Wistar Institute** · enrollment: 54 (actual)

## Conditions studied

- HIV
- HIV/AIDS

## Interventions

- **DRUG:** Peg-IFN-α2b

## Key facts

- **NCT ID:** NCT02227277
- **Lead sponsor:** The Wistar Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2015-02-11
- **Primary completion:** 2018-02-07
- **Final completion:** 2018-07-24
- **Target enrollment:** 54 (ACTUAL)
- **Last updated:** 2018-04-05

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02227277

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02227277, "Reducing Proviral HIV DNA With Interferon-a". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02227277. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*